Lanreotide

Lanreotide is a synthetic cyclic octapeptide somatostatin analog structurally related to octreotide but incorporating D-2-naphthylalanine in place of D-phenylalanine at position 1. This modification contributes to its unique self-assembling properties that enable sustained-release formulations without the microsphere technology required for octreotide LAR.

The compound binds preferentially to somatostatin receptor subtypes SSTR2 and SSTR5, producing similar biological effects to octreotide including suppression of growth hormone, IGF-1, glucagon, and various gastrointestinal hormones. Its receptor binding profile makes it effective for both acromegaly and neuroendocrine tumors.

Lanreotide's self-assembling formulation (Autogel) consists of the peptide in a supersaturated solution that forms a depot upon subcutaneous injection, providing sustained release over 4-6 weeks. This elegant pharmaceutical design eliminates the need for polymer-based delivery systems and enables simple syringe-based administration.

Beyond hormone suppression, lanreotide has demonstrated antiproliferative effects in neuroendocrine tumors, potentially through direct receptor-mediated effects on tumor cells and indirect effects on growth factor signaling. The CLARINET trial established lanreotide's ability to extend progression-free survival in gastroenteropancreatic neuroendocrine tumors regardless of functional status.